Clinical trial
A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)
NCT01725256 is registered in ClinicalTrials.gov with Aires Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)
- Lead sponsor
- Aires Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- November 30, 2012
- Completion date
- February 28, 2014
- Enrollment
- 29 (actual)
- Sites
- 25
Conditions
As the registry lists them; a condition with its own page is linked.